Long term follow up of clofazimine (Lamprene) in the management of reactive phases of leprosy

Abstract

Observations in 120 leprosy patients with reaction treated with Lamprene (clofazimine) for periods ranging from 3 months to 5 years are presented. Lamprene was found to be an effective therapy for ENL, acute neuritis, eye complications associated with reaction, epistaxis, haemoptysis and nasal discharge due to leprous rhinitis. No adverse effects were noticed in 3 women who were on continuous treatment with Lamprene immediately prior to their becoming pregnant, throughout pregnancy and puerperium. Except for hyperpigmentation of the child, no other deleterious effect on the foetus was noted. Two patients developed 'granulomatous enteritis' while on Lamprene. Bacterial clearance as judged by fall in BI was comparable to that seen in patients on dapsone 100 mg daily. After 6 months of continuous treatment, no recurrence of ENL was seen in any of the patients. There was significant improvement in motor and sensory functions in patients with acute neuritis in all types of leprosy.